Relfydess (RelabotulinumtoxinA) by Galderma receives OK for use in Europe. It will be available in 2025.
RelfydessTM (RelabotulinumtoxinA) is the first and only READY-TO-USE liquid neuromodulator created with PEARL technology. The results of the phase III READY clinical trial program demonstrate that Relfydess produced results maintained for six months, with the onset of action from the first day, both for expression lines and crow's feet.
It is the first and only ready-to-use liquid neuromodulator created with PEARL technology, designed to preserve the molecular integrity of the product and to provide a highly active, innovative and pure molecule. PEARL technology allows to reduce or eliminate the denaturation of some molecules during the manufacturing process. Therefore, the final product is purer and more stable and involves fewer steps and less manipulation during its production. Having a purer and more bioavailable molecule is essential to obtain better and longer lasting results over time.
Relfydess will be the first neuromodulator in Europe to receive initial approval for two indications, expression lines and crow's feet.
RelfydessTM is indicated for the temporary improvement of the appearance of moderate to severe expression lines of: gabella, forehead, eyes observed at maximum smile.
It will be available for use in 2025. We can't wait to be able to use it!
For informations +39 3516936538 or aemclinic@icloud.com
コメント